What is AAT Bioquest?
AAT Bioquest operates at the intersection of advanced chemistry and biological research, specializing in the development of high-performance fluorescent dyes and molecular probes. The company provides a comprehensive suite of bioconjugation solutions, including specialized crosslinkers and labeling reagents that are essential for modern laboratory workflows. By offering a robust portfolio of validated assay kits, AAT Bioquest empowers researchers to achieve high-fidelity results in complex experimental environments. Their market position is defined by a dedication to precision, supporting academic and commercial institutions in their pursuit of breakthrough discoveries through reliable, cutting-edge chemical reagents.
How much funding has AAT Bioquest raised?
AAT Bioquest has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in AAT Bioquest
PPP
Public-Private Partnership
What's next for AAT Bioquest?
With the infusion of this latest capital, AAT Bioquest is well-positioned to scale its operational capacity and accelerate the development of its next-generation molecular probe library. The strategic focus will likely shift toward enhancing global distribution channels and deepening its custom service offerings for biopharmaceutical partners. As the company transitions through this late-stage growth phase, the emphasis remains on maintaining technical superiority in the fluorescent labeling market while exploring new applications for its proprietary bioconjugation chemistry. This financial backing provides the necessary runway to sustain long-term research initiatives and maintain a competitive edge in the rapidly evolving life sciences landscape.
See full AAT Bioquest company page
